<DOC>
	<DOCNO>NCT02037776</DOCNO>
	<brief_summary>The purpose study assess efficacy safety Rikkunshito compare placebo Japanese subject Functional Dyspepsia .</brief_summary>
	<brief_title>The Efficacy Safety Study Rikkunshito Patients With Functional Dyspepsia</brief_title>
	<detailed_description />
	<mesh_term>Dyspepsia</mesh_term>
	<mesh_term>Gastritis</mesh_term>
	<criteria>Patients diagnose FD accord ROME III criterion ) Criteria fulfil last 3 month symptom onset least 6 month prior obtain inform consent ii ) Have receive upper endoscopy within last 6 month prior enrollment evidence structural/organic disease iii ) Must one follow symptom : 1 . Bothersome postprandial fullness 2 . Early satiation 3 . Epigastric pain 4 . Epigastric burning At least one FDrelated symptom Global Overall Symptom ( GOS ) scale ( bothersome postprandial fullness , early satiation , epigastric pain , epigastric burning ) ≥4 , whereas heartburn ≤3 . Total score depressionrelated symptom Hospital Anxiety Depression Score ( HAD ) ≤10 . Type visit : Outpatient Provides voluntary inform consent receive adequate explanation demonstrate thorough understanding nature study . Confirmed ulcer ( exclude scar ) malignant tumor upper GI Suspected organic lesion hepatobiliarypancreatic region cholelithiasis , hepatitis , pancreatitis History upper GI resection Serious complication ( liver , kidney , heart , blood disease metabolic disease ) Less year since test positive H. pylorus undergone successful eradication therapy Use prohibit medication Neuropsychiatric disorder Use plan use investigational drug Unable take drug orally History allergic reaction Kampo medicine Pregnant lactate woman plan conceive study period Deemed ineligible principal investigator subinvestigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Rikkunshito</keyword>
	<keyword>Double blind</keyword>
	<keyword>Functional dyspepsia ( FD )</keyword>
</DOC>